TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Cutia Therapeutics ( (HK:2487) ) is now available.
Cutia Therapeutics has announced that their Abbreviated New Drug Application for CU-40105, a self-developed topical finasteride spray for treating androgenetic alopecia, has been accepted by China’s National Medical Products Administration. This development is expected to enhance the company’s product offerings in scalp disease treatments, potentially allowing for a differentiated commercialization strategy and broader market coverage. The acceptance marks a significant step in expanding their product matrix and targeting diverse consumer needs in the androgenetic alopecia market.
The most recent analyst rating on (HK:2487) stock is a Hold with a HK$7.00 price target. To see the full list of analyst forecasts on Cutia Therapeutics stock, see the HK:2487 Stock Forecast page.
More about Cutia Therapeutics
Cutia Therapeutics is a company incorporated in the Cayman Islands, focusing on the development of therapeutic products, particularly in the field of scalp diseases. Their primary product offerings include innovative treatments such as the self-developed topical finasteride spray for androgenetic alopecia, aiming to provide alternative drug options with reduced systemic exposure.
Average Trading Volume: 696,999
Technical Sentiment Signal: Sell
Current Market Cap: HK$2.61B
For a thorough assessment of 2487 stock, go to TipRanks’ Stock Analysis page.